Medical Cannabis Moves to Schedule III as DEA Sets June Hearing

When the Justice Department quietly issued an order moving FDA-approved and state-licensed medical cannabis into Schedule III of the Controlled Substances Act, a lot of people outside the industry shrugged. Inside it, phones lit up. For anyone who has spent the last twenty years in this business — through the 2014 Cole Memo, the 2018 Farm Bill, the false starts of the SAFE Banking Act, and the endless "next year" promises on rescheduling — this is the first federal reclassification of cannabis since Richard Nixon's administration placed it on Schedule I in 1971. That is not a press release. That is a hinge in history.

Let me be precise about what happened, because the headlines have been sloppy. This order did not legalize cannabis. It did not touch adult-use recreational products. What it did was move FDA-approved marijuana medicines and state-licensed medical cannabis down to Schedule III — the same tier as ketamine, anabolic steroids, and Tylenol with codeine. The Drug Enforcement Administration also opened the door to the bigger fight, scheduling an administrative hearing for June 29, 2026 to consider rescheduling marijuana more broadly.

Why Schedule III is the whole ballgame for operators

If you want to understand why operators are giddy, you have to understand a four-digit number that has quietly strangled this industry: 280E. Section 280E of the federal tax code prohibits any business "trafficking" in a Schedule I or II substance from deducting ordinary business expenses. Rent, payroll, marketing, packaging — none of it is deductible. The result is that a dispensary can be profitable on paper, generous to its staff, and compliant in every way, and still hand the IRS an effective tax rate north of 70%.

I have watched good operators — people who did everything right — get buried by 280E. They couldn't reinvest, couldn't raise wages, couldn't survive a bad quarter. Moving medical cannabis to Schedule III removes 280E for qualifying medical operators starting in the 2026 tax year. The executive order behind this move even directs the IRS to consider retroactive relief for prior years. If that happens, it would return real money to operators who were taxed into a corner.

For two decades, 280E was the silent killer of cannabis businesses. Lifting it is the closest thing this industry has had to oxygen.

What it does — and doesn't — change

Here is where seasoned judgment matters. Adult-use cannabis, which is the bulk of the legal market in states like New York, is not covered by this order. So if you operate a recreational shop, your 280E problem hasn't vanished — yet. What has changed is the gravitational pull of the entire conversation. Once the federal government concedes that cannabis has accepted medical use, the intellectual foundation of Schedule I collapses. The June 29 hearing is where that argument gets made on the record.

The DEA has confirmed it will open new registration pathways for medical cultivators, manufacturers, testing labs, and distributors, building on a dispensary portal that went live at the end of April. That is the unglamorous plumbing of legitimacy — the forms and registrations that turn a tolerated industry into a regulated one.

The bigger picture: this resets everyone's risk calculus

The cannabis industry has spent a decade pricing in federal hostility. Banks stayed away. Institutional capital sat on the sidelines. Multistate operators carried 280E like a stone in a backpack. A move to Schedule III — even a partial, medical-only one — changes the risk calculus for all of them. Lenders who wouldn't return a call last year are now asking what a fully rescheduled market looks like. That shift in sentiment matters as much as the statutory change itself, because capital follows confidence.

For New York specifically, the timing is fortunate. The state's legal market has finally hit its stride, and a friendlier federal backdrop gives operators here more room to invest and compete. If you're a consumer, the near-term effect is subtle, but a healthier operator base eventually shows up as better selection and sharper pricing. You can already see how competitive the market has become by comparing live prices at licensed New York dispensaries or scanning the day's cannabis deals on High Today.

What to watch next

Three things will tell you whether this is a genuine turning point or another false dawn. First, the June 29 hearing — does the DEA move toward full Schedule III, or slow-walk it? Second, the IRS guidance on retroactive 280E relief, which could be worth millions to established operators. Third, whether Congress finally moves on banking access now that the executive branch has shifted. Any one of those would be significant. All three together would mark the moment the legal cannabis industry stopped being treated as a federal pariah.

The competitive ripple for New York operators

Don't mistake a medical-only reclassification for a local non-event. Reclassification reshapes the whole industry's capital flows, and New York sits squarely in the path. When multistate operators get relief from 280E on their medical operations and a friendlier federal backdrop, they free up cash and confidence — and they redeploy both into the markets with the best growth, which right now means states like New York. More investment means more competition, and more competition is exactly what drives the daily deals shoppers can already compare at licensed New York dispensaries.

It also raises the pressure on Albany. Once the federal government concedes that cannabis has accepted medical use, the political argument for continuing to tax and restrict the legal market into a corner gets weaker. Operators here will rightly ask why their state should keep treating a now-Schedule-III substance with maximum friction. I expect the rescheduling conversation to accelerate state-level reform debates across the country, and New York — with its scale and its equity ambitions — will be one of the loudest rooms. The businesses that win will be the ones tracking these shifts closely and positioning early, rather than waiting for certainty that never quite arrives.

I've learned to temper my optimism in this business — I've watched "imminent" reform evaporate more than once. But I've also never seen the federal government formally concede the medical legitimacy of this plant. That concession can't be un-made. The rest is timing. And in cannabis, timing has a way of arriving all at once.